成都圣诺生物科技股份有限公司董事会 关于独立董事独立性情况评估的专项意见 根据证监会《上市公司独立董事管理办法》《上海证券交易所科创板股票上 市规则》《上海证券交易所科创板上市公司自律监管指引第 1 号——规范运作》 的相关规定，成都圣诺生物科技股份有限公司（以下简称"公司"）董事会对公 司在任独立董事徐正松先生、唐英凯先生、刘霞女士的独立性情况进行了评估， 并出具如下意见： 成都圣诺生物科技股份有限公司 董事会 2025 年 4 月 24 日 公司于近日收到三位独立董事提交的《关于独立性情况的自查报告》，经核 查上述人员未在公司担任除独立董事以外的任何职务，也未在公司主要股东公司 担任任何职务，与公司及主要股东之间不存在利害关系或其他可能妨碍其进行独 立客观判断的关系，符合《公司法》《上市公司独立董事管理办法》等法律法规 以及《公司章程》对独立董事的任职要求，持续保持独立性，在任职期间不存在 影响独立性的情形。 ...

报告编制说明 1 contents 目录 | 报告编制说明 | 01 | | --- | --- | | 走进圣诺 | 03 | | 可持续发展治理 | 11 | 环境篇： 共护生态之美 结篇 01 02 03 04 | 环境合规管理 | | --- | | 能源与应对气候变化 | | 污染防治与生态系统保护 | | 资源利用与循环经济 | 社会篇 : 共绘美好蓝图 | 员工 | 37 | | --- | --- | | 产品安全与质量 | 52 | | 客户权益保障 | 58 | | 创新驱动 | 62 | | 供应链安全 | 68 | | 乡村振兴与社会贡献 | 69 | 治理篇 : 共筑发展之基 | 公司治理 | 73 | | --- | --- | | 商业道德 | 78 | | 风险内控 | 80 | | 党建引领 | 82 | | 未来展望 | 83 | | --- | --- | | 关键绩效表 | 85 | | 指标索引表 | 88 | | 读者反馈表 | 94 | 17 21 22 31 01 2024 年可持续发展报告 报告编制说明 02 报告编制说明 本报告是成都圣诺生物科技股份有限公司 ...

成都圣诺生物科技股份有限公司 2024 年度天健会计师事务所（特殊普通合伙）的履职情况评 估报告 成都圣诺生物科技股份有限公司（以下简称"公司"）聘请天健会计师事务 所（特殊普通合伙）（以下简称"天健"）作为公司 2024 年度财务报告出具审计 报告的会计师事务所。 根据财政部、国务院国有资产监督管理委员会、中国证券监督管理委员会颁 布的《国有企业、上市公司选聘会计师事务所管理办法》，公司对天健在 2024 年度的审计工作的履职情况进行了评估。具体情况如下： 一、会计师事务所的情况 （一）资质条件 天健具有良好的投资者保护能力，已按照相关法律法规要求计提职业风险基 金和购买职业保险。截至 2024 年末，累计已计提职业风险基金和购买的职业保 险累计赔偿限额合计超过 2 亿元，职业风险基金计提及职业保险购买符合财政部 关于《会计师事务所职业风险基金管理办法》等文件的相关规定 （三）执业记录 天健近三年存在执业行为相关民事诉讼，在执业行为相关民事诉讼中存在承 担民事责任情况。天健近三年因执业行为在相关民事诉讼中被判定需承担民事责 任的情况如下： | 原告 | 被告 | 案件时间 | 主要案情 | 诉讼进展 | | ...

1、 专项审计报告 2、 附表 委托单位：成都圣诺生物科技股份有限公司 审计单位：天健会计师事务所（特殊普通合伙） 联系电话：0571-89722900 目 录 | 一、非经营性资金占用及其他关联资金往来情况的专项 | | --- | 审计说明… 关于成都圣诺生物科技股份有限公司 非经营性资金占用及其他关联资金往来情况 汇总表的专项审计报告 目 录 非经营性资金占用及其他关联资金往来情况的 专项审计说明 天健审〔 2025 〕7911 号 成都圣诺生物科技股份有限公司全体股东: 我们接受委托,审计了成都圣诺生物科技股份有限公司(以下简称圣诺生物) 2024 年度财务报表,包括 2024年 12 月 31 日的合并及母公司资产负债表,2024 年度的合并及母公司利润表、合并及母公司现金流量表、合并及母公司所有者权 益变动表,以及财务报表附注,并出具了审计报告。在此基础上,我们审计了后 附的圣诺生物管理层编制的 2024年度《非经营性资金占用及其他关联资金往来 情况汇总表》(以下简称汇总表)。 一、对报告使用者和使用目的的限定 二、非经营性资金占用及其他关联资金往来情况汇总表 …………………………第３页 您可使用 ...

证券代码：688117 证券简称：圣诺生物 公告编号：2025-015 成都圣诺生物科技股份有限公司 关于召开2024年年度股东大会的通知 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、 召开会议的基本情况 （一） 股东大会类型和届次 2024年年度股东大会 （二） 股东大会召集人：董事会 （五） 网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自2025 年 5 月 15 日 至2025 年 5 月 15 日 股东大会召开日期：2025年5月15日 本次股东大会采用的网络投票系统：上海证券交易所股东大会网络投票 系统 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东大会召开当日的交易时间段，即 9:15-9:25,9:30-11:30，13:00-15:00；通过 互联网投票平台的投票时间为股东大会召开当日的 9:15-15:00。 （六） 融资融券、转融通、约定购回业务账户和沪股通投资者的投票程序 （三） 投票方式：本次 ...

证券代码：688117 证券简称：圣诺生物 公告编号：2025-004 成都圣诺生物科技股份有限公司 第四届监事会第二十四次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、监事会会议召开情况 1 成都圣诺生物科技股份有限公司（以下简称"公司"）第四届监事会第二十 四次会议通知于 2025 年 4 月 14 日以电话及邮件方式向各位监事发出，并于 2025 年 4 月 24 日在公司会议室以现场方式召开。会议由监事会主席曾德志先生召集 和主持。本次会议应出席监事 3 人，实际出席监事 3 人。本次会议的召集和召开 程序符合有关法律、法规、规范性文件和《公司章程》的有关规定。 二、监事会会议审议情况 经与会监事审议，做出如下决议： (一）审议通过《关于<公司 2024 年度财务决算报告及 2025 年度财务预算报 告>的议案》 经审议，监事会认为：公司董事会根据天健会计师事务所（特殊普通合伙） 出具的 2024 年审计报告及公司实际情况编制的《2024 年度财务决算报告及 2025 年度财务预算报告》，真实、 ...

成都圣诺生物科技股份有限公司（以下简称"公司"）第四届董事会第二十 五次会议通知于 2025 年 4 月 14 日以电话及邮件方式向各位董事发出，并于 2025 年 4 月 24 日在公司会议室以现场结合通讯方式召开。会议由公司董事长文永均 先生召集和主持。本次会议应到董事 9 人，实到董事 9 人。本次会议的召集和召 开程序符合有关法律、法规、规范性文件和《成都圣诺生物科技股份有限公司章 程》（以下简称"《公司章程》"）的规定，会议决议合法、有效。 证券代码：688117 证券简称：圣诺生物 公告编号：2025-003 成都圣诺生物科技股份有限公司 第四届董事会第二十五次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、董事会会议召开情况 （二）审议通过《关于<公司 2024 年度总经理工作报告>的议案》 公司总经理文永均先生对公司 2024 年度经营情况、2025 年度经营计划等事 项向董事会做了汇报，公司董事会同意《2024 年度总经理工作报告》。 表决结果：同意 9 票，反对 0 票，弃权 0 票， ...

Financial Performance - The company's operating revenue for Q1 2025 was CNY 184,337,043.36, representing a 77.15% increase compared to CNY 104,057,251.91 in the same period last year[4] - Net profit attributable to shareholders was CNY 47,119,700.22, a significant increase of 186.06% from CNY 16,472,225.12 year-on-year[4] - The net profit after deducting non-recurring gains and losses reached CNY 47,943,063.53, up 213.63% from CNY 15,286,389.83 in the previous year[4] - Basic earnings per share increased to CNY 0.42, reflecting a growth of 180.00% compared to CNY 0.15 in the same quarter last year[5] - Diluted earnings per share also rose to CNY 0.43, marking an increase of 186.67% from CNY 0.15 year-on-year[5] - Total operating revenue for Q1 2025 reached ¥184,337,043.36, a significant increase of 77.2% compared to ¥104,057,251.91 in Q1 2024[20] - Net profit for Q1 2025 was ¥47,080,862.26, representing a 186.5% increase from ¥16,450,135.99 in Q1 2024[21] - Basic earnings per share for Q1 2025 were ¥0.42, compared to ¥0.15 in Q1 2024, reflecting a 180% increase[21] - The company reported a total comprehensive income of ¥47,080,862.26 for Q1 2025, compared to ¥16,450,135.99 in Q1 2024, marking a 186.5% increase[21] Assets and Liabilities - The company's total assets at the end of the reporting period were CNY 1,664,893,442.81, a slight increase of 1.03% from CNY 1,647,900,520.96 at the end of the previous year[5] - As of March 31, 2025, the company's total assets amounted to approximately CNY 1.66 billion, an increase from CNY 1.65 billion as of December 31, 2024[15] - The company's cash and cash equivalents decreased to CNY 175.23 million from CNY 218.71 million, representing a decline of about 19.8%[15] - Accounts receivable increased significantly to CNY 153.21 million, up from CNY 101.75 million, indicating a growth of approximately 50.6%[15] - Inventory decreased slightly to CNY 293.37 million from CNY 304.75 million, a reduction of about 3.9%[15] - The company's non-current assets totaled approximately CNY 956.80 million, up from CNY 929.69 million, reflecting an increase of about 2.9%[16] - Short-term borrowings decreased to CNY 192.64 million from CNY 200.16 million, a decline of about 3.8%[16] - Total liabilities decreased to ¥698,646,924.57 in Q1 2025 from ¥729,578,120.25 in Q1 2024, a reduction of 4.2%[20] - Total equity attributable to shareholders increased to ¥966,246,518.24 in Q1 2025 from ¥918,343,435.50 in Q1 2024, an increase of 5.2%[20] Research and Development - Research and development expenses totaled CNY 5,047,373.95, down 48.66% from CNY 9,830,599.42 in the same period last year[5] - The proportion of R&D expenses to operating revenue decreased to 2.74%, down 6.71 percentage points from 9.45%[5] - Research and development expenses decreased to ¥4,839,101.81 in Q1 2025 from ¥9,416,771.26 in Q1 2024, a decline of 48.7%[20] Cash Flow - The net cash flow from operating activities was CNY 8,761,105.21, a decrease of 27.33% compared to CNY 12,056,553.34 in the previous year[4] - Cash flow from operating activities for Q1 2025 was ¥8,761,105.21, down from ¥12,056,553.34 in Q1 2024[22] - Net cash flow from investing activities was -$26.91 million, a decrease from -$101.24 million year-over-year[23] - Cash inflow from financing activities totaled $60 million, compared to $37.32 million in the previous period[23] - Cash outflow for debt repayment was $78.98 million, significantly higher than $2.08 million last year[23] - The net cash flow from financing activities was -$22.26 million, contrasting with a positive $33.34 million in the prior year[23] - The ending cash and cash equivalents balance was $164.93 million, slightly up from $162.06 million year-over-year[23] - Total cash inflow from investment activities was $68.71 million, compared to $19.39 million previously[23] - Total cash outflow from investment activities was $95.62 million, down from $120.63 million last year[23] - Cash flow from operating activities was not detailed in the provided content, indicating a focus on investment and financing[23] Future Outlook - The increase in revenue and profit was primarily driven by the sales of Semaglutide and Tirzepatide products[8] - The company plans to focus on market expansion and new product development in the upcoming quarters[20] - The company plans to implement new accounting standards starting in 2025, which may affect future financial reporting[23] Miscellaneous - The company has not reported any changes in the top 10 shareholders due to securities lending activities[13] - There are no significant reminders or additional important information regarding the company's operational status during the reporting period[13] - The company reported a significant increase in other receivables, which decreased to CNY 5.54 million from CNY 7.97 million, a decline of about 30.5%[15]

Financial Performance - The company's operating revenue for 2024 was CNY 456,070,000.10, representing a year-on-year increase of 4.84% compared to CNY 435,021,032.33 in 2023[26]. - The net profit attributable to shareholders for 2024 decreased by 28.88% to CNY 50,023,708.92 from CNY 70,337,139.39 in 2023[26]. - The net cash flow from operating activities fell by 70.19% to CNY 25,273,281.32, down from CNY 84,783,208.00 in the previous year[26]. - The basic earnings per share for 2024 was CNY 0.45, a decrease of 28.57% from CNY 0.63 in 2023[27]. - The company's total assets increased by 25.25% to CNY 1,647,900,520.96 at the end of 2024, compared to CNY 1,315,724,989.56 at the end of 2023[26]. - The company's net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 45,612,403.87, down 24.24% from CNY 60,205,816.35 in 2023[26]. - The company's operating costs increased by 21.60% to CNY 191.70 million, primarily due to increased overseas sales of raw materials[107]. - The gross margin for the pharmaceutical manufacturing segment was 58.99%, reflecting a decrease of 6.17 percentage points year-on-year[112]. - The company reported a total of 2,134,650 shares held by directors, supervisors, and senior management at the beginning of the year, which increased to 2,257,303 shares by the end of the year, a net increase of 122,653 shares[188]. Research and Development - Research and development expenses accounted for 11.06% of operating revenue in 2024, up from 8.00% in 2023, indicating a strategic focus on innovation[27]. - R&D expenses totaled 50.46 million yuan, an increase of 45.05% year-on-year, accounting for 11.06% of operating revenue[37]. - The company is actively engaged in the research and development of new peptide drugs, with a focus on addressing unmet medical needs in areas such as diabetes and cancer[49]. - The company has established a robust pipeline with various projects at different stages, including 5 projects in clinical trials and 3 projects that have been approved for market[49]. - The company has developed 21 self-researched peptide raw materials, with 14 varieties obtaining production licenses or activation records in the domestic market[51]. - The company has received 28 new utility model patents and 1 invention patent during the reporting period[39]. - The company has submitted applications to the FDA for several products, including Eptifibatide and Ganirelix, which are in various stages of development[84]. - The company is focusing on the integration of raw material and formulation capabilities, enhancing competitiveness in the pharmaceutical industry[75]. Market Expansion and Strategy - ChengDu BiotecCo. plans to expand its market presence in Southeast Asia, with an investment of RMB 100 million allocated for this initiative[19]. - The company aims to enhance its market expansion efforts and invest in new product development to drive future growth[26]. - The company is exploring new strategies for market penetration, including the development of customized drug formulations for specific client needs[49]. - The company is actively pursuing market expansion both domestically and internationally through strategic partnerships and registrations[51]. - The company aims to strengthen its market presence by expanding its domestic and international marketing strategies[168]. - The company plans to enhance its domestic formulation market by optimizing sales channels and accelerating the promotion of strategic products to increase market share[171]. - The company is considering strategic acquisitions to enhance its product portfolio, with a budget of 300 million allocated for potential mergers and acquisitions[190]. Sustainability and Corporate Governance - ChengDu BiotecCo. is committed to sustainability, aiming to reduce its carbon footprint by 20% over the next three years through eco-friendly practices[19]. - The company published its fourth ESG report, showcasing its commitment to social responsibility and governance practices[46]. - The company has established a governance structure that complies with relevant laws and regulations, ensuring the legality and effectiveness of meeting resolutions[185]. - The company maintains a robust information disclosure system, ensuring timely and accurate communication with investors[182]. - The company is committed to building a sustainable development environment and fostering honest relationships with investors and stakeholders[183]. Product Development and Innovation - The company is focusing on the research, production, and sales of peptide drugs, with 2 products approved for commercialization and 23 in clinical trial stages[141]. - The company has successfully launched its own formulations in the domestic market and has clients for formulations in Mexico and the US[52]. - The company is advancing the production line project with an annual capacity of 395 kg of peptide raw materials, which is currently in the production line verification stage[41]. - The company has established partnerships with well-known pharmaceutical enterprises such as Fresenius, Masung, and DAEHAN, expanding its raw material product sales to regions including Europe, the United States, and South Korea[21]. - The company is focusing on expanding its product pipeline and enhancing its R&D capabilities to drive future growth[84]. Financial Management and Investments - The company plans to continue investing in new product development and market expansion despite current financial pressures[106]. - The total investment during the reporting period was 18,047,648 RMB, a decrease of 58.42% compared to the previous year[154]. - The company has invested a total of 49,447,648 RMB in private equity funds during the reporting period[157]. - The company will conduct a semi-annual evaluation report on the "quality improvement and efficiency enhancement" action plan for 2024[200]. - The company plans to apply for a maximum comprehensive credit limit of RMB 3,000,000 to Chengdu Bank[200]. Shareholder and Management Structure - The board of directors consists of 9 members, including 3 independent directors, ensuring a balanced and effective governance structure[178]. - The total remuneration for all directors, supervisors, and senior management at the end of the reporting period amounted to 5.70 million RMB[196]. - The total remuneration for core technical personnel at the end of the reporting period was 3.36 million RMB[197]. - The company has appointed several independent directors with extensive experience in finance and management, enhancing its governance structure[193]. - The company is focusing on stock incentive plans to motivate key personnel and enhance performance[188].

证券代码：688117 证券简称：圣诺生物 公告编号：2025-005 成都圣诺生物科技股份有限公司 关于2024年度利润分配及资本公积转增股本方案及 2025年中期分红规划的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 每股分配/转增比例：每 10 股派发现金红利人民币 1.40 元（含税），同 时以资本公积金转增股本每 10 股转增 4 股。 本次利润分配及资本公积转增股本以实施权益分派股权登记日登记的总 股本为基数，具体日期将在权益分派实施公告中明确。 在实施权益分派的股权登记日前公司总股本发生变动的，拟维持每股分 配比例、转增比例不变，相应调整分配总额和转增总额，并将另行公告具体调整 情况。 本次利润分配及资本公积转增股本方案及 2025 年中期分红规划尚需提 交公司 2024 年年度股东大会审议，审议通过之后方可实施。 公司未触及《上海证券交易所科创板股票上市规则（2024 年 4 月修订）》 （以下简称"《科创板股票上市规则》"）第 12.9.1 条第一款第（八）项规定 的可能被实施其他 ...